Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Ploegsteert – page 24

1 758 clinical trials in Ploegsteert, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Ploegsteert at a glance
1 758
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 758 trials in Ploegsteert

Open in trial search

Study of obinutuzumab treatment for patients with non-infectious cryoglobulinemia vasculitis who did not respond to or cannot tolerate rituximab

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Study of hypertonic saline solution and mannitol to improve recovery in patients with traumatic brain injury and high risk of intracranial hypertension

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Mannitol
  • Sponsor:Centre Hospitalier Universitaire De Nantes

Cardiomyopathy

Recruiting

Study of Nucresiran in Adults with Transthyretin Amyloidosis with Cardiomyopathy to Evaluate its Effects on Survival and Heart Problems

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Nucresiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Study of momelotinib in patients with VEXAS syndrome and myelodysplastic syndrome who are dependent on or do not respond to steroid treatment

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Momelotinib Dihydrochloride Monohydrate
  • Sponsor:Groupe Francophone Des Myelodysplasies

Study of ficerafusp alfa and pembrolizumab as first treatment for patients with PD-L1-positive recurrent or metastatic head and neck cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ficerafusp alfa
  • Sponsor:Bicara Therapeutics Inc.

IgA nephropathy

Recruiting

Study of felzartamab compared to placebo in adults with IgA nephropathy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate
  • Sponsor:Biogen Idec Research Limited

Study of MK-2214 to slow disease progression in people with early Alzheimer's disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Florquinitau (18F)
  • Sponsor:Merck Sharp & Dohme LLC

Study of GHZ339 for treatment of moderate to severe atopic dermatitis

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:GHZ339
  • Sponsor:Novartis Pharma AG

Myocarditis

Recruiting

Study of anakinra compared to placebo for treating acute myocarditis in children admitted to intensive care units

Registered drug
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Anakinra
  • Sponsor:Assistance Publique Hopitaux De Paris

Study of zolbetuximab combined with paclitaxel and ramucirumab for patients with previously treated CLDN18.

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Zolbetuximab
  • Sponsor:UZ Leuven

Study of dupilumab injections to reduce airway inflammation in adults aged 40-85 with chronic obstructive pulmonary disease

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study of zoldonrasib with daraxonrasib, pembrolizumab and chemotherapy in patients with RAS G12D-mutant non-small cell lung cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Revolution Medicines Inc.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Ploegsteert

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical trials focusing on proton pump inhibitor (PPI) management strategies in primary care settings, examining optimal approaches for medication reduction in patients with chronic usage patterns.

  • Functional Dyspepsia
  • Gastroesophageal Reflux
  • Chronic Heartburn Management

The research explores alternative treatment approaches, including on-demand medication use and alginate-based therapy, comparing their effectiveness to traditional deprescribing methods.

02 Primary Care Innovation

Studies evaluating strategic approaches to medication optimization in primary care, with a focus on reducing long-term dependency on acid-suppressing medications.

  • Medication Deprescribing
  • Patient-Centered Care
  • Treatment Optimization

This research aims to establish evidence-based guidelines for managing chronic medication use while maintaining therapeutic effectiveness.

03 Therapeutic Management

Investigation into alternative treatment strategies for common gastrointestinal conditions, focusing on comparative effectiveness of different therapeutic approaches.

  • Medication Management
  • Treatment Alternatives
  • Clinical Outcomes

The research evaluates various therapeutic options to identify optimal treatment pathways for patients requiring long-term acid suppression therapy.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.